Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 68Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 56Neoplasm Metastasis 55Breast Neoplasms 51Multiple Myeloma 42Colorectal Neoplasms 40Pancreatic Neoplasms 33Carcinoma, Renal Cell 33Myelodysplastic Syndromes 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 25Glioblastoma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Urinary Bladder Neoplasms 22Lymphoma 22Burkitt Lymphoma 21Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Hepatocellular 19Glioma 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Skin Squamous Cell Carcinoma × Specimen Handling × 1 year × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡